Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + paclitaxel + carboplatin is a combination chemotherapy and targeted therapy regimen used primarily in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) and has also been studied in advanced non-small cell lung cancer. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting tumor cell proliferation and survival. Paclitaxel is a microtubule-stabilizing agent that disrupts mitosis, leading to apoptosis of rapidly dividing cells. Carboplatin is a platinum-based chemotherapeutic that causes DNA crosslinking, resulting in inhibition of DNA synthesis and function. This combination leverages different mechanisms to maximize anti-tumor activity: cetuximab blocks EGFR signaling, while paclitaxel and carboplatin act as cytotoxic agents against dividing tumor cells[1][2][4][5].
- Brand names
- TaxolParaplatinErbitux
- Other names
- PCC regimenPCE regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)DNA
Beyond the preview
Go deeper on cetuximab + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + paclitaxel + carboplatin.